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Abstract
Background: The primary objective of this study was to investigate if extended antibiotic treatment against
bacterial vaginosis (BV) together with adjuvant lactobacilli treatment could cure BV and, furthermore, to investigate
factors that could cause relapse.
Methods: In all, 63 consecutive women with bacterial vaginosis diagnosed by Amsel criteria were offered a much
more aggressive treatment of BV than used in normal clinical practice with repeated antibiotic treatment with
clindamycin and metronidazole together with vaginal gelatine capsules containing different strains of lactobacilli
both newly characterised and a commercial one (10
9 freeze-dried bacteria per capsule). Oral clindamycin treatment
was also given to the patient’s sexual partner.
Results: The cure rate was 74.6% after 6 months. The patients were then followed as long as possible or until a
relapse. The cure rate was 65.1% at 12 months and 55.6% after 24 months. There was no significant difference in
cure rate depending on which Lactobacillus strains were given to the women or if the women were colonised by
lactobacilli. The most striking factor was a new sex partner during the follow up period where the Odds Ratio of
having a relapse was 9.3 (2.8-31.2) if the patients had a new sex partner during the observation period.
Conclusions: The study shows that aggressive treatment of the patient with antibiotics combined with specific
Lactobacillus strain administration and partner treatment can provide long lasting cure. A striking result of our
study is that change of partner is strongly associated with relapse of BV.
Trial registration: ClinicalTrials.gov: NCT01245322
Background
Bacterial vaginosis (BV) is a disease with unknown aetiol-
ogy, characterised by loss or reduction of lactobacilli and
increased numbers of anaerobes and Gram-negative rods
[1]. It is one of the most frequent vaginal infections, and
the most common symptom is malodours discharge.
The currently recommended treatment regimes for BV
are oral or vaginal metronidazole or vaginal clindamycin
[2]. Treatment efficacy is supposed to be high. In a Meta-
analysis, the expected cure rate after one month was 70%-
80% for metronidazole [3] and 82% for clindamycin [4].
However, in clinical practice these high efficacy rates are
rarely observed. Based on our own review of published
data, the efficacy is not more than 60% after 4 weeks [5].
Likewise in a follow up study, only 42% were BV free 12
months after therapy [6]. In order to reduce the number
of patients who experienced relapse, Sobel et al treated
women with recurrent BV with vaginal metronidazole gel
for ten days, compared to the normal five days [7].
Women who responded to therapy were then treated with
metronidazole gel twice weekly or placebo for 4 months,
followed for another 3 months without therapy. By the
end of 4 months, 75% were cured in the treatment group
compared to 59% in the placebo group, but after 7 months
only 49% in the treatment group versus 25% in the placebo
group remained cured.
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bacterial microbiota of the vagina and have a physiologi-
cal role in maintaining a low pH (<4.5), thus protecting
against invasion by other micro-organisms [8]. Recent
studies, using not only traditional phenotypic methods
but also genotyping, have convincingly shown the most
common vaginal lactobacilli species to be L. crispatus,
L. gasseri, L. iners and L. jensenii [9] where L. crispatus
is associated to a normal flora and L. iners more often
to BV [10].
The treatment suggestion by Reid et al. [11] i.e. giving
oral capsules of L. reuteri (formerly L. fermentum)a n d
L. casei var. rhamnosus, was reported to be successful in
37% of the treated women as compared to 13% given
placebo. In a study from Nigeria, the same strains of lacto-
bacilli given orally after a one week course of oral metroni-
dazole cured 88% of women with BV after 30 days
compared to 45% in the metronidazole/placebo group
[12]. These efficacy results have not been obtained by any
other group.
We have previously performed a treatment study with
addition of vaginal lactobacilli that did not improve the
initial cure rate but the relapse rate was nearly 20% lower
in the Lactobacillus treated group [13]. Because of the
lower relapse rate noted in this study, we designed a new
explorative study with novel, well characterised Lactoba-
cillus strains of human vaginal origin [9].
The primary objectives of this study were to characterise
lactobacilli of human vaginal origin and to investigate if
more extended antibiotic treatment against BV, together
with adjuvant lactobacilli treatment, could increase the
cure rate and furthermore, to investigate factors that could
influence relapse.
Methods
Lactobacillus strains
A total of 110 isolates (51 L. crispatus,4 5L. gasseri and 14
L. jensenei) previously isolated from the vaginal tract of 15
healthy Swedish women [9] were initially included in the
study for characterisation and selection of strains for a
colonisation study (Table 1). Lactobacillus iners isolates
were discarded since these bacteria require special growth
requirements, precluding future large scale production
and commercial application. Lactobacilli were grown in
MRS or Rogosa agar in anaerobiose or in MRS broth in a
standing condition at 37°C.
Genotyping by REP-PCR and AP-PCR
The Lactobacillus strains were initially typed using PCR
amplification on the bacterial repetitive extragenic palin-
dromic DNA sequences (REP-PCR). Chromosomal DNA
was isolated from lactobacilli grown in MRS using the
DNAeasy kit (Qiagen GmbH, Hilden, Germany) accord-
ing to the manufacturer protocol for gram positive
bacteria. The primers REP1R-I (5’-IIIICGICGICAT-
CIGGC-3’) and REP2-I (5’-ICGICTTATCIGGCCTAC-
3’) were used based on the reproducibility, band intensity
and discriminative power [14]. The amplification mixture
contained 25 ng template DNA, 1 μM of each primer,
1 X Green GoTaq™ Flexi reaction buffer (Promega,
Madison, Wisconsin, USA) and 200 μM of each dNTP,
3 mM MgCl2, and 2.5 U GoTaq™ DNA Polymerase for a
total of 50 μl. Bacterial DNA was amplified by PCR using
the same thermocycler (GeneAmp
® PCR System 9700,
Applied Biosystem) and the cycling parameters described
by Ventura and Zink [14]. Ten μlo ft h eP C Rp r o d u c t
was electrophoresised on a 2% agarose gel containing 1 ×
TAE (Tris acetate-EDTA) and the DNA was visualised by
UV transillumination using a Molecular Imager Gel
Doc™ system (BioRad, Hercules, CA).
As the L. crispatus strains from women 4, 21 and 23
shared identical REP-PCR profiles, the strains were
further differentiated using RAPD (Rapid amplified poly-
morphic DNA)-PCR with the primers RAPD3 (5’-
ACGAGGCAC-3’) (primer OPL-5, [15] and RAPD4 (5’-
CCGCAGCCAA-3’) (primer 1254, [16]). Furthermore,
during the colonisation study, positive profile results
obtained by REP-PCR were confirmed by two different
RAPD PCR using two primers: RAPD3 and RAPD4 for
L. crispatus strains; RAPD4 and RAPD6 (5’-TGGGCG
TCAA-3’) (primer OPL-2, [15]) for L. gasseri strains;
and RAPD1 (5’-ATGTAACGCC-3’) (primer P2, [17])
and RAPD4 for L. rhamnosus. Each primer was used at
0.5 μM employing the same PCR mixture as described
for the REP-PCR. The cycling program was: initial dena-
turation at 94°C for 2 min; 35 cycles of denaturation at
94°C for 1 min; annealing at 35°C for 1 min; extension
at 72°C for 2 min and a final extension at 72°C for
8m i n .T e nμl of PCR reaction was electrophoresised on
a 2% agarose gel containing 1 X TAE (Tris acetate-
EDTA).
Characterisation of Lactobacillus strains
Eighteen Lactobacillus strains isolated from Swedish
women and showing different REP- and RAPD PCR pro-
files were selected and tested for growth rate, aggregation,
H2O2 production, hemolysis, antibiotic susceptibility and
the presence of plasmids.
The growth rate was evaluated by inoculating a 10 ml
MRS tube adjusted to an OD600 of 0.04 and measuring the
time of growth from OD600 0.04 to OD 1.0 (late exponen-
tial phase). The value was used to calculate an approxi-
mate doubling time.
In order to measure aggregation, bacteria were grown
until an OD600 1.0 in 10 ml MRS. The tubes were vortexed
for 1 min and the aggregation was scored after 30 min in a
standing position. The aggregation was scored as follows:
no aggregation (0), presence of flakes (1), sedimented
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clear supernatant (3).
H2O2 production by Lactobacillus strains was tested
with MRS agar supplemented with 0.25 mg of tetra-
methylbenzidine (Sigma, St. Louis, Mo.) per ml and 0.01
mg of horseradish peroxidase (Sigma) per ml [18]. H2O2
production was visually scored as strongly positive (3),
intermediate positive (2) weakly positive (1), or negative
(0) according to the intensity of blue colour development.
T h eh a e m o l y t i ca c t i v i t yw a se v a l u a t e do nC o l u m b i ab l o o d
agar plates containing 5% human or sheep blood following
48 h incubation at 37°C in aerobic, microaerobic (5% CO2)
and anaerobic conditions. Two Streptococcus pyogenes clini-
cal isolates (S. pyogenes PU1735 and S. pyogenes svt)
obtained from Clinical Microbiology, Department of Clini-
cal and Experimental Medicine clinical University of
Linköping were used as positive controls.
The minimum inhibitory concentration (MICs) of ten
antibiotics was determined by the E-test method according
to the manufacturer’s instruction for lactobacilli (AB Bio-
disk; Solna, Sweden). The breakpoints (susceptible/resis-
tant) were determined in accordance with the Clinical and
Laboratory Standards Institute guidelines for gram-positive
microorganisms [19].
Plasmids were isolated from a 10-ml culture grown until
OD600 0.8 using the following steps: treatment of cells
with lysozyme (10 mg/ml) and mutanolysin (80 u/ml), cell
lysis, neutralisation, extraction with phenol/chloroform/
iso-amylalcohol and precipitation with ethanol. The
nucleic acid pellet was washed once with 70% ethanol,
dissolved in 100 μl of TE buffer (10 mM Tris-HCl, pH 8.0
a n d1m ME D T A )c o n t a i n i n g1 0 0μg/ml of RNase A.
Ten μl was run on a 1% agarose gel and the presence of
plasmids was visualized by UV transillumination.
Lactobacilli used for treatment
Nine of the vaginal Lactobacillus strains isolated from
healthy Swedish women and characterised in the present
study were selected for the clinical trial. The lactobacilli
were fermented, lyophilised, and dispensed as a mixture
of three different strains (10
9/capsule) in gelatin capsules
according to GMP standard (Gruppo Clerici SACCO SS.
r.l., Cadorago Italy together with Bifodan A/S, Hun-
dested, Denmark). Other strains from commercial pro-
ducts, currently used for treatment of BV, were also
tested for comparison. These strains include L. gasseri
(Lba EB01-DSM 14869) and L. rhamnosus (Lbp PB01-
DSM 14870) contained in the commercially available
EcoVag
® vaginal capsules (10
8 CFU/capsules) (Bifodan
A/S, Denmark). Both these Lactobacillus strains were
initially isolated from healthy women in Norway. Cap-
sules containing the EcoVag
® strains plus another one,
L. gasseri DSM 15527, also isolated from healthy women
at the same time and characterised by Bifodan. The sec-
ond probiotic preparation used was LaciBios
® (oral cap-
sules containing Lactobacillus rhamnosus GR-1 and
Table 1 Typing of vaginal Lactobacillus isolates
a
Woman
b Isolate species REP-PCR type RAPD-PCR type RAPD-PCR type
RAPD3 RAPD4
C 4B1, 4R4, 4R5, 4R6, 4M6 L. crispatus 1I A
D 5B1, 5B2, 5B3, 5R4, 5R5, 5R6, 5M7, 5M8, 5M9 L. gasseri 2
E 6B1, 6B2, 6B3, 6R4, 6R5, 6R6, 6M9 L. gasseri 3
6M7, 6M9 L. gasseri 4
F 7B1, 7B2, 7B3, 7R4, 7R5, 7R6, 7M7, 7M8, 7M9 L. gasseri 5
G 8B1, 8B2, 8B3, 8R4, 8R5, 8R6, 8M7, 8M8, 8M9 L. crispatus 6
H 9R4, 9M7, 9M8, 9M9 L. crispatus 7
J 12B1, 12B2, 12B3, 12R4, 12R5, 12R6, 12M7, 12M8, 12M9 L. jenseneii 8
K 13B1, 13B2, 13B3, 13R4, 13R5, 13R6, 13M7, 13M8, 13M9 L. crispatus 9
L 15R4, 15R5, 15R6, 15M7, 15M8, 15M9 L. gasseri 10
M 16B1, 16R5, 16R6 L. gasseri 11
16B2 L. crispatus 12
N 18B1, 18B2, 18B3, 18R4, 18R5, 18R6, 18M7, 18M8 L. crispatus 13
P 20B31, 20B32, 20B33, 20R34, 20R35, 20R36, 20M39 L. gasseri 14
20M37, 20M38 L. gasseri 15
Q 21R44, 21R45, 21R46, 21M47, 21M48, 21M49 L. crispatus 1I I A
R 22B41, 22B42, 22R45, 22M48, 22M49 L. jenseneii 16
S 23B31, 23B32, 23B33, 23R34, 23R35, 23R36, 23M37, 23M38, 23M39 L. crispatus 1I I B
a The different REP-PCR types were numbered from 1 to 16. Isolates from women 4, 21 and 23 were further differentiated by RAPD-PCR with primer 3 (type I and
II) and RAPD 4 (type A and B).
b Nomenclature according to Vásquez et al 2002.
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9/capsule)). These
Lactobacillus strains have been described in the studies
by Reid and collaborators [11,20].
Women were divided in seven groups that received
capsules containing two to three Lactobacillus strains as
follows. Group 0: EcoVag
® capsule containing L. gasseri
DSM 14869 and L. rhamnosus DSM 14870; Group 1:
L. crispatus 4R5, L. gasseri 20M39, and L. jenseneii 22B42;
Group 2: L. crispatus 23B33, L. gasseri 6M9,L .j e n s e n e i i
12B1; Group 3: L. crispatus 21M49, L. gasseri 6M9 and
L. crispatus 8R6; Group 4: L. gasseri DSM 14869, L. rham-
nosus DSM 14870 and L. gasseri DSM 15527; Group 5:
L. gasseri DSM 14869, L. rhamnosus DSM 14870, L. gasseri
DSM 15527; Group 6: LaciBios
® femina containing
L. rhamnosus GR-1 and L. reuteri RC-14. Group 0 to 4
received capsules intra vaginally while groups 5 and 6 took
the capsules orally.
Clinical Study
The study was conducted at an outpatient private gynae-
cological clinic in Drammen, Norway from January 2007
until January 2011. All women with symptomatic BV ful-
filling the inclusion criteria were consecutively offered to
participate in a prospective study of adjuvant lactobacilli
given in addition to antibiotics. Women included were
regularly menstruating women, 18 years or older, with
normal gynaecological status, not pregnant or breast-feed-
ing and without signs of other genital tract infections.
Exclusion criteria were patients with hormonal IUD with-
out regular menstruation; women infected with Chlamy-
dia trachomatis,o rTrichomonas vaginalis,o rw i t ha
clinical candida infection.
Study sample
A total of 76 patients were included in the study. The
mean age was 33.7 years with a range of 18-55 years. The
diagnosis of BV was based on Amsel criteria. Of the 76
patients, 13 were lost to follow up so that the study at
hand consists of 63 patients.
Clinical method
At inclusion, women had a routine gynaecological exami-
nation with a non-lubricated speculum and a vaginal
ultrasound. A sample of vaginal secretion was analysed
for vaginal pH using special pH strips (range 3.8-5.0).
The diagnosis of BV was based on Amsel criteria [21], i.e.
fulfilling at least 3 of 4 criteria; thin homogenous dis-
charge, vaginal pH above 4.5, positive amine test, and
presence of clue cell during microscopical investigation
using a phase contrast microscope. A vaginal sample was
taken and air-dried. At inclusion, vaginal samples for
determining Chlamydia trachomatis infection were per-
formed using strand-displacement amplification (CT
amplified DNA assay; Becton-Dickinson) according to
the local laboratory routine. Samples for Neisseria
gonorhoeae culture were only taken when deemed clini-
cally motivated.
Treatment
After signing the informed consent form, women were
given a seven days course of daily 2% vaginal clindamycin
cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd)
together with oral clindamycin 300 mg BID for 7 days
(Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin
treatment was also given to the patient’s sexual partner
[22], however the patient’s partner did not sign any
informed consent forms. Directly after the clindamycin
treatment, a new treatment with vaginal gelatine capsules
containing 10
8-10
9 freeze-dried lactobacilli for 5 days was
started. If menstruation was to occur during treatment, it
was suggested that the patient would wait until next
menstrual cycle before she started the treatment. After
the next menstruation, a new treatment with vaginal
metronidazole for 5 days (Zidoval gel 75 g, Meda AS,
Norway) was initiated followed by 5 more days with Lac-
tobacillus instillation. After the second menstruation, the
patients were given a new course of vaginal metronida-
zole gel (Figure 1). The evaluation of treatment efficacy
was performed after the last treatment course.
Follow up
After every menstruation the patients took a self
swabbed vaginal culture and a glass smear that was air
dried and sent in a sealed envelope to the laboratory
using the same method as in an earlier study [23]. The
vaginal sample was collected after the bleeding had
ceased and before the start of treatment.
The vaginal samples were sent by regular mail from
Norway to the Clinical Microbiology laboratory, Linköp-
ings University, Sweden where it was cultured. All
recovered lactobacilli were identified to the genus level
Lactobacillus by Gram staining, colony morphology and
negative catalase test and were subsequently frozen at
-70°C and transported to the Clinical Immunology
laboratory at the Karolinska hospital in Huddinge where
additionnal characterisation was performed. All recov-
ered lactobacilli isolates were again cultured and identi-
fied to the species level by amplifications of 16S rDNA
regions using species-specific primers. Identification to
the strain level was carried out using REP-PCR and
RAPD PCR (as described above) to test if they were the
s a m es t r a i n sa st h o s ep r o v i d ed in the lactobacilli-con-
taining capsules. These tests were performed blindly,
without knowledge of the treatment the women had
received.
E v e r yw o m a nw a sf o l l o w e du pb yap h o n ec a l lf r o m
the investigation nurse and asked about treatment com-
plications and concomitant medication. If the patient
h a df a i l e dt os e n das a m p l e ,i tw a sr e c o r d e da sm i s s i n g
but she was reminded and asked to send in a new
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Page 4 of 14sample after the next menstruation. Each patient col-
lected a total of 6 vaginal samples.
After six menstrual cycles, women were scheduled for
a follow up visit to the clinic. Normally the vaginal sam-
ples were taken once every 28
th day and the follow up
time of 6 menstrual cycles would be 5 and half month
but for some women 6 menstruation cycles could take
longer than 6 months, thus, we report this as a 6-month
follow up.
The women were then followed up to 12 months and
they were offered a new visit at 24 months, or before, in
the case of symptomatic relapse.
Microscopical investigation
Each vaginal sample was rehydrated with normal saline
and investigated under a phase contrast microscope with
400 times magnification and with a microscopic area of
0.016 mm
2. The approximate numbers of bacteria were
recorded as well as the presence of clue cells together with
the number of vaginal leucocytes. Each slide was classified
according to Hay/Ison classification [24,25] to either nor-
mal, intermediate or BV. All microscopic evaluations were
performed after that the women had been on clinical
visits.
Definition of cure
To be considered cured, the women had to have none of
Amsels critera fulfilled at the clinical visit after 6-9
months. All women with clinical relapse (fulfilment of
Amsel criteria) at the clinical visit were regarded as treat-
ment failures and were re-treated with clindamycin and
metronidazole. Treatment efficacy is reported both as
cure after 6, 12 and 24 months, and as time to relapse
illustrated with survival analysis with Life table analysis.
Some women had treatment failure already at the third
month as seen on the self taken sample. These were con-
sidered as treatment failures if the Hay/Ison score was 3,
a Hay/Ison score of 2 was designated as improved and a
score of 1 as cure. A Hay/Ison score of 0 and 4 were
regarded as equal to a score of 1 during the follow up
periods. As all microscopic investigations were per-
formed after that the women had been on a clinic visit
and re-treatment was not initiated on the microscopic
results.
Study design
The study was performed as a consecutive treatment,
open label, follow-up study.
Statistical methods
Not all patients collected a vaginal smear every month
and in case of missing data during the first follow up
month, the procedure “last observation carried forward”
(LOCF) was used. “Time from treatment to relapse” has
been calculated in months and was used to explore dif-
ferences in time to relapse between groups by survival
analysis with Kaplan Meier procedure. A logistic regres-
sion analysis was performed and an Odds ratio (OR) with
95% confidence interval (CI) was calculated. All compari-
sons both between and within groups was performed
two-tailed with a significance level of 5%. All the analyses
in this study were performed in PASW (SPSS) v.18 and
in accordance with the principal of intention to treat
(ITT).
Ethical approval
The study was approved by the southeast regional Ethics
Committee in Oslo, Norway. To recruit women with
BV, we advertised in local newspapers asking for women
suffering from malodorous discharge.
Results
Typing and characterisation of vaginal lactobacilli
Analysis of the lactobacilli previously isolated from healthy
women showed that only one Lactobacillus species of the
same REP-PCR type was generally found among the iso-
l a t e sf r o me a c hw o m a n .T h eo n l ye x c e p t i o n sw e r et h e
Figure 1 Time schedule of the treatment and follow up. Even if the patient had a relapse at the self taken samples (3-6 months) she did not
receive treatment until the clinical visit that determined with Amsel criteria at the clinical visit after 6 months.
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Page 5 of 14women E and P who both carried L. gasseri isolates with
two different REP-PCR profiles and woman M who carried
two species (L. gasseri and L. crispatus) (Table 1). Strains
from different women showed different REP-PCR profiles
apart from the L. crispatus strains from woman C, Q and
S. These L. crispatus strains could further be differentiated
by performing two RAPD-PCR with the primers RAPD3
and RAPD4 (Table 1). A total of 18 different genotypes
were identified by using a combination of REP-PCR and
RAPD-PCR.
Eighteen Lactobacillus strains with different PCR types
were selected for further characterisation and were
scored according to properties that would promote their
colonisation (auto aggregation) and antimicrobial capa-
city (H2O2 production), guarantee their safety for human
use (abscence of plasmid, absence of hemolysis and no
antibiotic resistance) and possibility for large scale pro-
duction (growth rate) (Table 2). Four strains containing
plasmids (5M8, 13B2, 15M7, 16B2) and one strain with
ambiguous blood hemolysis results (18R5) were dis-
carded. Although the hemolysis could not be classified as
b-hemolysis, it was decided to not pursue further studies
with this strain for potential safety reasons. None of the
strains were resistant to ampicillin, cefuroxime, imipe-
nem, gentamicin, erythromycin, chloramphenicol, tetra-
cycline, or rifampicin. All the tested lactobacilli were
resistant to metronidazole and several of the strains
(10 of 18 strains) were resistant to cefoxitin. High level of
resistance to these antibiotics has been previously
reported and is considered as natural resistance in lacto-
bacilli [26].
Nine Lactobacillus strains of different species and pre-
senting the highest scores were selected for the clinical
trial: three L. gasseri (6M8, 6M9, 20M39), four L. crispatus
(4R5, 8R6, 21M49, 23B33) and two L. jenseneii (12B1,
22B42) strains (Table 3).
Clinical treatment with antibiotics and lactobacilli
Demographic and behavioural characteristics
Of the 76 patients enrolled, 13 were lost during the fol-
low up. Considering that 14 women got pregnant during
this period, the 17% drop out rate is comparable to
other studies [7,6]. The demographic and behavioural
characteristics of the 63 participants that completed the
s t u d ya r es h o w ni nT a b l e3 .A l lt h ew o m e ni n c l u d e d
were Caucasians. There was no difference in the above
Table 2 Characterisation of vaginal Lactobacillus strains
PCR type strain Species Doubling time
a Autoaggregation
b H2O2
c Hemolysis Plasmid
e Antibiotic resistance
f Total score
g
23B33 L. crispatus 92 (1) 3 3 a - MZH, FX 7*
21M49 L. crispatus 91 (1) 3 2 a - MZH 6*
8R6 L. crispatus 83 (2) 3 0 a - MZH 5*
4R5 L. crispatus 109 (1) 3 0 a - MZH 4*
9M9 L. crispatus 102 (1) 1 2 a - MZH 4
13B2 L. crispatus 96 (1) 2 1 a + MZH 0
16B2 L. crispatus 113 (1) 2 1 a + MZH 0
18R5 L. crispatus 95 (1) 2 3 ?
d - MZH, FX 0
6M9 L. gasseri 69 (2) 3 1 a - MZH, FX 6*
6M8 L. gasseri 71 (2) 3 0 a - MZH, FX 5*
20M39 L. gasseri 68 (2) 0 1 a - MZH, FX 3*
20M37 L. gasseri 71 (2) 0 1 a - MZH, FX 3
16B1 L. gasseri 122 (0) 1 1 a - MZH, FX 2
7B3 L. gasseri 183 (0) 0 1 a - MZH 1
5M8 L. gasseri 77 (2) 3 1 a + MZH, FX 0
15M7 L. gasseri 68 (2) 1 0 a + MZH, FX 0
22B42 L. jensenii 85 (2) 3 2 a - MZH, FX 7*
12B1 L. jensenii 71 (2) 1 2 a - MZH, FX 5*
a Doubling time: more than 120 min (score 0), between 90-120 min (score 1), between 60-90 min (score 2)
bAutoaggregation: no aggregation (score 0), presence of flakes (score 1), sedimented flakes but cloudy supernatant (score 2), sedimented flakes and clear
supernatant (score 3).
c H2O2 production: strongly positive (score 3), intermediate positive (score 2) weakly positive (score 1), or negative (score 0) according to the intensity of blue
colour development.
d Slight lysis of human blood cells were observed for 18R5 when grown in anaerobiosis.
e Presence (+) or absence (-) of plasmid
f Antibiotics to which the Lactobacillus strains are resistant among the 10 tested. Metronidazole (MHZ), cefoxitin (FX).
g Total score for a Lactobacillus strain is the sum of scores for doubling time, auto-aggregation and hydrogen peroxide production (max. value 8). Strains showing
slight hemolysis (18R5) and presence of plasmid (5M8, 13B2, 15M7, 16B2) were scored 0.
*Strains with the highest score selected for the clinical trial.
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Page 6 of 14Table 3 Demographic and clinical characteristics in the study population at enrolment (n = 63)
Groups
a 01 2 3456 Total
EcoVag
® Lc 4R5 Lc 23B33 Lc 21M49 Lg14869 Lg 14869 LaciBios
®
Lg 14869 Lg 20M39 Lg 6M9 Lg 6M9 Lr 14870 Lr 14870 Lr GR-1
Lr 14870 Lj 22B42 Lj 12B1 Lc 8R6 Lg 15527 Lg 15527 Lr RC-14
Vaginal Vaginal Vaginal Vaginal Vaginal Oral Oral
n=9 n=1 2 n=1 0 n=1 0 n=9 n=4 n=9 n=6 3
Mean age (range) 34.2 (19-
55)
36.6 (26-48) 35.3 (25-45) 32.7 (25-39) 33.3 (21-
46)
33.0 (25-38) 34.7 (21-
45)
34.2 (19-
55)
Patients with history of BV (no.) 3 6 5 5301 2 3 ( 3 6 .5%)
Patients with Mobiluncus on microscopy (no.) 4 6 5 3422 2 6 ( 4 1 .3%)
Length of symptoms of BV (months, mean and range)
c 10.7 (1-24) 10.7 (1-48) 14.1 (1-60) 7.9 (1-48) 18.3 (2-60) 3.3 (2-6) 9.5 (1-24) 11.3 (1-60)
Patients with new relation (no.) 8 6 (2
divorced)
8( 1
divorced)
6( 2
divorced)
63 ( 1
divorced)
4 36 (57.1%)
New relation before symptoms appear (no.) 8 6 8 6633 3 5 ( 5 5 .6%)
Length of symptoms of BV among women with new relation (months, mean and
range)
10.5(1-24) 6.5 (1-12) 14.4 (1-60) 4.5 (2-11) 11.3 (2-46) 3.3 (2-6) 11.2 (1-24) 8.2 (1-46)
a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii
b Capsules contain the two strains from EcoVag
® plus an additional strain, L. gasseri DSM 15527, belonging to Bifodan A/S
c One patient in group 3, 5, 6 and two patients in group 4 could not give any information since how long time she had symptoms of BV.
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4characteristics between the women in the different treat-
ment groups.
Twenty-three women (36.5%) had been treated for BV
previously with a mean time of 3.8 years before starting
the study. There was no data on how many times the
women had been previously treated for BV. The median
time that the symptoms of BV had started was 5 months
before the start of the study with a range of 1-60 months
and the average time was 10.8 months.
Women reported that they had met a new partner in 36
cases (57.1%) and 6 women (9.5%) had recently been
divorced and only 21 (33.3%) had the same sexual partner.
The median time for the new relationship was 6 months
with a range of 1-48 months and the mean time was
12 months.
Among the 36 women that had a new partner, one
woman reported that she had symptoms of BV before she
met her new partner. Among the other 35 patients, it is
then possible to calculate an “incubation time”.T h a ti st h e
difference between the time that the patient starts her new
relationship and the beginning of symptoms of BV. The
median time was 2 months with a range of 1-22 months
and a mean time of 3.8 months.
Colonisation
Colonisation with any given lactobacilli was observed in
17 out of the 43 patients that received intravaginal lacto-
bacilli (Table 4). Four women were not included in the
analysis of colonisation as they did not provide enough
samples. The women receiving EcoVag
® (Group 0) were
colonised by L. rhamnosus 14870 in 6 out of 8 cases
(75%). The strain persisted more than 2 months in three
patients, i.e. about 2 weeks after stopping its administra-
tion, and until Month 3 and 5 in two other patients (one
and three months after stopping the treatment respec-
tively). Of the women receiving the characterised lactoba-
cilli isolated from Swedish women (Group 1 to 3), the
L. crispatus strains were the ones showing the best colo-
nisation (Table 4). Although colonising a lower propor-
tion of women (around 33%), L. crispatus 4R5 (Group 1),
L. crispatus 23B33 (Group 2), and L. crispatus 8R6
(Group 3) persisted until Month 6 in 7 out of 9 women
colonised by one of these strains i.e. 4 months after stop-
ping the treatment. Of the women receiving a mixture of
L. rhamnosus 14870, L. gasseri 14869 and L. gasseri DSM
15527, only two were colonised either by L. rhamnosus
14870 or L. gasseri 14869. None of the women that took
Table 4 Colonisation of the vaginal tract by administered Lactobacillus
Group Treatment Number of women included per group
a Number of women colonised by each strain (%)
0 Vaginal 8 Any strain 6 (75%)
L. gasseri Lba EB01-DSM 14869 0 (0%)
L. rhamnosus Lbp PB01-DSM 14870 6 (75%)
1 Vaginal 9 Any strain 2 (22%)
L. crispatus 4R5 2 (22%)
L. gasseri 20M39 1 (11%)
L. jenseneii 22B42 0 (0%)
2 Vaginal 9 Any strain 4 (44%)
b
L. crispatus 23B33 4 (44%)
L. gasseri 6M9 1(11%)
L. jenseneii 12B1 0 (0%)
3 Vaginal 9 Any strain 3 (33%)
b
L. crispatus 8R6 3 (33%)
L. gasseri 6M9 1 (11%)
L. crispatus 21M49 0 (0%)
4 Vaginal 8 Any strain 2 (25%)
b
L. gasseri (Lba EB01-DSM 14869) 2 (25%)
L. rhamnosus (Lbp PB01-DSM 14870) 1 (13%)
L. gasseri DSM 15527
a 0 (0%)
5 Oral 4 Any strain 0 (0%)
L. gasseri (Lba EB01-DSM 14869) 0 (0%)
L. rhamnosus (Lbp PB01-DSM 14870) 0 (0%)
L. gasseri DSM 15527
a 0 (0%)
6 Oral 9 Any strain 0 (0%)
L. rhamnosus GR-1 0 (0%)
L. reuteri RC-14 0 (0%)
a Only women that sent samples regularly were included in the caculation.
b Some women were colonise by two strains.
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Page 8 of 14the Lactobacillus preparation orally (Group 5 and 6) got
colonised.
Clinical outcome
Of the 63 patients that completed the study, 28 had
relapses after 24 months. The cure rate was 74.6% after 6
months, 65.1% after 12 months and 55.6% after 24 months
(Table 5).
There was no significant difference in cure rate
depending on which lactobacilli were given to the
women (Figure 2). Furthermore, no correlation was
found between colonisation with administered lactoba-
cilli and the cure rate either at 6, 12 or 24 months after
the start of the study.
All patients’ sexual partners, except two, accepted the
oral clindamycin treatment. In one case, the couple had
separated and partner treatment was not indicated. After a
year, they started the same relationship again and this case
was calculated as a new sexual relationship. In the second
case, the partner refused to take any medicine. The patient
had a microscopic relapse already at 4 months and a clini-
cal relapse at the 6-month visit. This case is reported as
having the same sexual partner. Two women reported the
same male sexual partner but a new female sexual partner
and are thus reported as having a new sexual partner.
During the follow up time, a total of twenty-two patients
had changed to new sexual partner. Of the 22 patients
with a new partner, only 5 had no relapse (cure of 22.7%)
compared to 30 of the 41 (73.2%) that did not change
partner, OR = 9.3 (95% CI: 2.8-31.2). Survival analysis
(Figure 3) showed that women who reported a new sexual
partner during follow-up had significantly shorter time to
relapse with a Log Rank test (p < 0.001).
A l s oam u l t i p l el o g i s t i cr e g r e s s i o ns h o wt h a tc h a n g e d
to new sexual partner during follow up was significantly
associated to have a relapse but not age, earlier treat-
ment of BV, presence of Mobiluncus before entering the
study, a new relation before entering the study, lactoba-
cilli given or whether or not the patient were colonised
with any lactobacilli (Table 6). Of the 28 women with
relapse, 21 had one relapse and five had two relapes.
Two women had 4 and 5 relapses during the follow up
period.
D u r i n gt h es t u d y ,o n l yo n es e v e r ea d v e r s ee v e n t
occurred, a case of diarrhoea in group 1 that caused the
patient to stop treatment. There were no more candida
infections than expected normally (10%).
Discussion
The purpose of this study was to optimise the treatment
of BV using extended antibiotics administration com-
bined with administration of lactobacilli. By giving the
patient a more aggressive treatment, we could obtain a
6-month cure rate of 74.6%, a 12-month cure rate of
65.1% and a 24-month cure rate of 55.6%. Interestingly,
we could not find any difference in cure rate whether or
not it was a recurrent BV. These findings are surprising
as it has always been suggested in the literature that
recurrent BV is more difficult to treat [7,27].
There are many treatment studies of BV that report
cure rates of 90% but such a high cure rate is not seen
in clinical practice [5]. As diagnostic tests for BV are
subjective, one can question a cure higher than 70%
after one month. From our own meta-analysis, a 4-week
cure rate is never better than 60% [5]. Most studies
r e p o r ta2w e e ko r4w e e kc u r er a t ea n dt h e r ea r ev e r y
few studies that report a longer follow up than 4 weeks.
As our treatment lasted 2 months, our 6-month cure
rate corresponds to 4 months, or 4 menstruations, after
the cessation of treatment. Our study could thus be
compared to the Sobel study [7] where 88% of the
women who clinically responded to a ten days treatment
with 0.75% metronidazole gel were randomly assigned to
metronidazole or placebo twice weekly for 4 months.
Three months after cessation of treatment, the cure rate
was 49% in the treatment group and 25% in the placebo
group. But as only 88% were initially cured the compar-
able cure rate would be 43% in the treatment group,
and this cure rate should be compared to our cure rate
Table 5 Clinical outcome
Groups
a 0 1 2 3 4 5 6 Total
EcoVag
® Lc 4R5 Lc 23B33 Lc 21M49 Lg14869, Lg 14869 LaciBios
®
Lg 14869 Lg 20M39 Lg 6M9 Lg 6M9 Lr 14870, Lr 14870 Lr GR-1
Lr 14870 Lj 22B42 Lj 12B1 Lc 8R6 Lg 15527 Lg 15527 Lr RC-14
Vaginal Vaginal Vaginal Vaginal Vaginal Oral Oral
n=9 n=1 2 n=1 0 n=1 0 n=9 n=4 n=9 n=6 3
6-month cure (no. and percentage) 8 (89%) 9 (75%) 8 (80%) 6 (60%) 6 (67%) 2 (50%) 8 (89%) 47 (74.6%)
12-month cure (no. and percentage) 7 (78%) 7 (58%) 6 (60%) 7 (70%) 6 (67%) 2 (50%) 6 (67%) 41 (65.1%)
24-month cure (no. and percentage) 5 (56%) 4 (33%) 6 (60%) 6 (60%) 6 (67%) 2 (50%) 6 (67%) 35 (55.6%)
Number of patients with new relation
during follow up (no. and percentage of all)
2 (22%) 4 (33%) 4 (40%) 4 (40%) 2 (22%) 3 (75%) 3 (33%) 22 (34.9%)
a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii
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Page 9 of 14of 74.6%. In another follow up study from Australia,
only 31% had a Nugent score of less than 3, 12 months
after therapy with one week of oral metronidazole [6].
In comparison to these studies, our 6-month cure rate
of nearly 75% is markedly superior.
Recurrence rates for BV beyond 12 months have been
reported in very few studies. In one of them, non-pregnant
women were treated with oral metronidazole for 10 days.
The patients were treated until they were cured at a follow
up visit and for some patients, the metronidazole treat-
ment was repeated up to 3 times before all patients were
cured. Outpatients’ attendance was retrospectively
reviewed, and follow-up at 6 years revealed a cumulative
recurrence rate of BV of 53% where 73% of the recur-
rences had occurred within 12 months, i.e. a 12-month
cure rate of 63% but starting from only cured patients [28].
Marcone et al have carried out adjuvant treatment with
lactobacilli following treatment with oral metronidazole
for 7 days [29]. The cure rate at 6 and 12 months was
higher (>80%) than in the present study. However, the
cure rate in women receiving the traditional treatment
with metronidazole only was also much higher (around
70%) than the one previously reported in other studies
(less than 36%) (Table 7) [6,7]. The definition of cure in
their study was not based on Nugent or Hay/Isons scoring
and only women who use natural methods of contracep-
tion were included, making it difficult to compare with
other studies. The women selected in their study were
p r o b a b l ye n g a g e di nam o r es t a b l er e l a t i o n s h i pa n dl e s s
prone to change of partners and relapses. In a subsequent
study by Marcone et al, long-term treatment with lactoba-
cilli for 6 months resulted in a cure rate of 91% 6 months
after stopping the treatment [30]. The study could be criti-
cized for the same reason as the earlier study [29] but it
could also be that the two courses of lactobacilli for 5 days
used in the present study is a too short treatment and that
a long-term treatment is necessary to obtain a stable bio-
film in the vagina.
If we exclude studies that report a 2 or 4-week cure
r a t e ,t h et r e a t m e n tp r o p o s e di nt h ep r e s e n ts t u d y
describes one of the best cure rates that has ever been
Figure 2 Survival analysis with Life table showing the
difference in cure rate between vaginal and oral
administration of different Lactobacillus preparations.N o
statistical difference is seen. Group 0: EcoVag
® capsule containing L.
gasseri DSM 14869 and L. rhamnosus DSM 14870; Group 1: L.
crispatus 4R5, L. gasseri 20M39, and L. jenseneii 22B42; Group 2: L.
crispatus 23B33, L. gasseri 6M9, L. jenseneii 12B1; Group 3: L. crispatus
21M49, L. gasseri 6M9 and L. crispatus 8R6; Group 4: L. gasseri DSM
14869, L. rhamnosus DSM 14870 and L. gasseri DSM 15527; Group 5:
Oral (the same group as the vaginal group 4) L. gasseri DSM 14869,
L. rhamnosus DSM 14870, L. gasseri DSM 15527; Group 6: oral
LaciBios
® femina containing L. rhamnosus GR-1 and L. reuteri RC-14.
Figure 3 Survival analysis with Kaplan-Meier showing that
there were significantly more relapses in patients who report a
new sexual partner during follow up. Log rank < 0.001. Patients
that are censored means that they have not completed the 24-
month follow up. For some women the 24-month follow up is not
done until 30 month. That is why some patients are reported as 30
month.
Table 6 Multiple logistic regression model where relapse
within 24 months was outcome variable
Variable OR 95% confidence interval
Age 1.1 1.0 1.2
Lactobacillus mix used for treatment 0.6 0.4 1.0
Mobiluncus at entry of the study 0.7 0.2 3.1
Pregnancy or major operation 1.3 0.6 2.8
New sexual partner during follow up 52.4 5.3 516.7
BV before study 1.3 0.3 5.8
New partner before study 0.4 0.1 1.2
Colonisation by lactobacilli 0.2 0.0 1.4
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Page 10 of 14reported. Our treatment suggestion is extremely aggres-
sive and one must ask if this aggressive treatment is justi-
fied. For many patients, however, BV is a burden that
causes a high morbidity and it takes a long time and
much effort in order to be cured. Often the women are
treated with many courses of antibiotics so in the end,
the difference to our aggressive treatment is that we give
all antibiotics at one time instead of spreading it out over
a longer time. The risk associated with aggressive antibio-
tic treatment is subsequent infection with Clostridium
difficile. Clindamycin is a drug that is often associated
with a risk for colitis but other antibiotics such as penicil-
lin, ampicillin, cephalosporin and fluoroquinolones can
all precipitate this disorder when used long term. As we
only gave one course of treatment for 7 days with clinda-
mycin, followed by two vaginal treatments with metroni-
dazole, we think that our treatment regimen does not
carry a high risk of acquiring Clostridium difficile infec-
tion [31] and during our study, only one patient had to
withdraw treatment because of diarrhoea. Recurrent BV
is troublesome and there have been only a few published
studies on how to handle recurrent BV [6,27,32-36] with
different suggestions as how to handle this problem.
Women are often given treatment similar to suppressive
treatment of chronic vulvo-vaginal candida infection [37].
It is not easy to perform a study in young women that
continues for a period of 24 month. During this follow
up, 14 women became pregnant and 5 underwent major
surgery such as hysterectomy (data not shown). This
could certainly influence the results of our 24 month
cure rate at follow up and this has to be taken into con-
sideration. As some patients still come to our clinic we
have registered 4 more relapses (2 because of a new rela-
tionship) but these have been after more than 30 months
after the first treatment. As we give the same aggressive
treatment in the case of a relapse, only 2 women had
more than 2 relapses. In at least one case, she had a sex-
ual partner that was not monogamous.
Several clinical trials have been performed to investigate
whether specific strains of lactobacilli, administered either
orally or intra-vaginally, in combination with antibiotics or
not, are able to colonise the vaginas of women with bac-
terial vaginosis and to improve symptoms and/or signs of
bacterial vaginosis [12,29,38,39]. Our previous study with
adjuvant EcoVag
® vaginal capsule treatment showed that
lactobacilli could increase the cure rate at 6 months by
nearly 20% (from 46% to 65%). However, only the women
who responded to treatment were included in that study
[13]. If we consider the women who were re-treated
already after the first month, the cure rate drops to 53% in
women treated with lactobacilli compared to 39% in the
placebo treated group. Since a placebo group was included
in the previous study, we did not include this group in the
present one for ethical reasons. However, the cure rate
Table 7 Study results of suppressive treatment of BV
Cure rate after
Study Treatment >1 month 3 months 6 months 12 months
Sobel 1993 [50] Oral metronidazole 7 days 25%
Topical clindamycin 7 days 38%
Boris 1997* [28] Oral metronidazole 10 days (for some 3 times) 63%
Eriksson 2005** [23] Topical clindamycin 3 days + lactobacilli tampons 57%
Topical clindamycin 3 days + placebo tampons 60%
Sobel 2006 [7] 10 days vaginal metronidazole + twice weekly for 4 months 43%
10 days vaginal metronidazole + placebo 19%
Bradshaw 2006 [6] Oral metronidazole 7 days 46% 36% 31%
Schwebke 2007 [51] Metronidazole gel twice weekly for 6 months 33%
Marcone 2008 [29] Oral metronidazole 7 days 71% 67%
Oral metronidazole 7 days + Lactobacillus rhamnosus for 2 months 88% 83%
Larsson 2008 [13] Topical clindamycin 7 days + lactobacilli 53%
Topical clindamycin 7 days + placebo 39%
Reichman 2009 [52] Triple treatment with oral nitroimidazole 65% 50%
21 days boric acid intravaginal and
Metronidazole gel 20 weeks (6 month treatment)
Ehrnström 2010 [37] Vaginal clindamycin + 5 types of lactobacilli 50%
Marcone 2010 [30] Oral metronidazole 7 days 74% 69%
Oral metronidazole 7 days + Lactobacillus rhamnosus for 6 months 96% 91%
This study Oral and vaginal clindamycin + vaginal metronidazole + lactobacilli 74.6% 65.1%
*Only cured patients were followed and some were treated 3 times.
**minimum 2 menstruations periods.
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Page 11 of 14obtained with vaginal administration of the new prepara-
tion tested was similar to the results obtained with
EcoVag
® capsules. Among the new characterised Lactoba-
cillus strains tested, only the L. crispatus strains were able
to colonise. The strains colonised a lower number of indi-
viduals than L. rhamnosus DSM 16870 from the Ecovag
®
capsule (30% vs 75%) but for a longer period (up to four
months after stopping the treament). In comparison,
the well studied probiotic strains L. crispatus CTV-05,
L. rhamnosus GR-1 and L. fermentum RC-14 have been
reported to colonise between 20 and 40% of the non anti-
biotic treated women 4-weeks post intravaginal adminis-
tration [40-42]. In a more recent study, vaginal capsules
containing a mixture of L. gasseri LN40, L. fermentum
LN99, L. casei subsp. rhamnosus LN113 and P. acidilactici
LN23 were administered for five days to women after con-
ventional treatment with clindamycin. Following the first
menstruation after Lactobacillus administration, 53% of
the women were colonised by any of the five strains but
only 26% after the second menstruation. In accordance
with our results, no correlation was found between coloni-
sation and treatment result of BV. The difference in colo-
nisation of the vaginal tract by the probiotic lactobacilli
might depend on factors such as vaginal intercourse and
the microflora at enrollement [40].
Oral treatment with Lactobacillus rhamnosus (GR-1)
and Lactobacillus reuteri (RC-14) have been shown to
be extremely effective over a four week follow up period
with a 90% cure [12]. In our study, however, oral treat-
ment with the same lactobacilli did not performed as
well over a long follow up period (67% cure).
Verstraelen et al. have reviewed the epidemiology of BV
in relation to sexual behavior and concluded that BV in
some acts as an STD or SED (sexually enhanced disease)
and with frequency of intercourse being the critical factor
[43]. A striking result of our study is that change of part-
ner is strongly associated with BV, giving strong support
to the notion of BV as a STD associated condition with
consequence for treatment/partner treatment. In the
study of Bradshaw [6], the authors found that having a
regular sex partner was associated with a higher recur-
rence rate whereas having a new sex partner was asso-
ciated with a lower recurrence. They suggested that
women treated for BV are reinfected by their regular
partner but not by new partners who would then be less
likely to carry the causative agent for BV. The discrepan-
cies between these two studies could be explained by the
fact that we treated the partners with clindamycin. How-
ever, according to published studies, there is no evidence
that partner treatment is efficacious [44]. The most
quoted studies are the Scandinavian studies by Vejtorp
[45] and Moi [46] where the authors used 2 grams of
metronidazole at day 1 and 3 given to the female and to
the male either as placebo or metronidazole in the same
dose. They reported cure rates of 75-77% regardless of
w h e t h e rt h ep a r t n e rw a st r e a t e do rn o t .B o t hs t u d i e s
were carried out at a STD clinic and none of the studies
controlled for a new partner during the follow up period.
This treatment regimen of metronidazole (2 grams, day 1
and 3) has been used worldwide but in fact this treatment
has never been evaluated in a placebo-controlled study.
Three other studies have reported a tendency towards a
better cure rate if the partner was treated [47-49]. The
o n l ys t u d yt h a tu s e dc l i n d a m y c i nr e p o r t e da1 0 % ,n o n -
significant, increase in cure rate after treating the partner
with oral clindamycin [22]. So as a conclusion from our
study and from the critical review of the literature we
suggest that partner treatment should be used more
often.
It is surprising that women tend not to seek care for
symptoms of BV directly when symptoms appear. The
mean time of beginning of symptoms was 11.3 months
(median time 6 months) with a range of 1-60 months,
prior to diagnosis. We have no explanation for this but
if this is the same in all countries it could be a possible
explanation why STI clinics have difficulties to find a
possible connection between a new sexual partners and
symptoms of BV. As 35 women reported that they had
symptoms of BV after they started a new relationship
it was possible to calculate an “incubation time”.T h i s
“incubations time” is only speculative but nevertheless
interesting, since it is only a median of 2 months.
Conclusion
The study shows that aggressive treatment of the patient
with antibiotics combined with Lactobacillus administra-
tion can provide a long lasting cure. A striking result of
our study is that a change of partner is strongly associated
with relapse of BV giving support for the notion that BV is
an STD and that the patient’s sexual partner needs to be
treated. The new Lactobacillus preparation tested were as
good as the commercial EcoVag
® product when adminis-
tered intra vaginally but vaginal colonisation observed for
some strains did not seem to influence the cure rate.
Further studies with extended treatment with different
preparations of lactobacilli and larger cohorts will have to
be performed to evaluate the relationship between coloni-
sation by lactobacilli and cure of BV.
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